| المساهمون: |
[Ríos-Tamayo R] Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. [Soler JA] Department of Hematology, HospitalUniversitari Parc Taulí de Sabadell, Catalonia, Spain. [García-Sánchez R] Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain. [Pérez Persona E] Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain. [Arnao M] Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [García-Guiñón A] Department of Hematology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Domingo A] Department of Hematology, Hospital General de Granollers, Granollers, Spain. [González-Pardo M] Medical Department, Janssen-Cilag España, Spain. [de la Rubia J] Hospital Universitari i Politècnic La Fe, Valencia, Spain. Hematology Department, Universidad Católica'San Vicente Mártir', Valencia, Spain. CIBERONC CB16/12/00284,Valencia, Spain. [Mateos MV] Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Salamanca, Spain, Hospital General de Granollers |
| الوصف: |
Relapsed-refractory multiple mieloma; Monoclonal antibodies; Observational multicenter study Mieloma múltiple recidivant-refractari; Anticossos monoclonals; Estudi observacional multicèntric Mieloma múltiple recidivante-refractario; Anticuerpos monoclonales; Estudio multicéntrico observacional Objectives: To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. Methods: This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. Results: A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (≥PR) and complete response or better (≥CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the ≥ PR and ≥ CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. Conclusions: The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials. Keywords: Relapsed-refractory multiple myeloma; daratumumab; monoclonal antibodies; real-world; standard of care. |
